We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Stem cells—a hard sell to investors.
- Authors
Giebel, Lutz B.
- Abstract
The article informs that a lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists. Human degenerative diseases present a large unmet medical need, and the market potential for successful therapies is great. The most successful and common cell therapies performed today are bone marrow transplants either from donors or self. What commercial products exist have not lived up to their market potential. Stem cell therapy is a subset of cell therapy, and companies developing cell therapies have historically disappointed investors.
- Subjects
STEM cells; INVESTORS; COMMERCIAL products; PRODUCT safety; CELLULAR therapy; BONE marrow; PRODUCT lines
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 7, p798
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0705-798